Brazilian researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) have made significant strides in cancer immunotherapy by engineering natural killer (NK) cells to be more potent and precise against tumors. Utilizing the NK-92 cell line, the team designed chimeric antigen receptors (CARs) incorporating costimulatory domains such as 2B4 and DAP12, which amplify the cells’ activation signals. This innovation addresses key limitations in traditional CAR therapies, particularly for blood cancers, where CAR-T cells have shown promise but CAR-NK cells remain underexplored. The study, published in *Frontiers in Immunology*, demonstrates that these modifications render NK cells “primed for attack,” markedly improving their cytotoxicity against tumor cells in vitro. By focusing on intracellular signaling mechanisms, the researchers overcame challenges like suboptimal activation, paving the way for more effective, off-the-shelf immunotherapies that could reduce reliance on patient-specific cells and minimize side effects such as cytokine release syndrome.

To further refine this approach, the team integrated pharmacological control using dasatinib, a tyrosine kinase inhibitor that temporarily halts NK cell activity, allowing for reversible modulation. Preclinical experiments in animal models revealed that CAR-NK cells with 2B4-DAP12 enhancements, combined with dasatinib pretreatment, exhibited superior tumor growth inhibition compared to conventional designs. This dual strategy—optimizing activation signals while enabling on-demand suppression—holds potential for safer, more adaptable treatments, especially in solid tumors where NK cell persistence is crucial. Supported by the São Paulo Research Foundation (FAPESP) and affiliated with the University of São Paulo’s Ribeirão Preto Medical School, this collaborative effort underscores the evolving landscape of cell-based therapies. For Indian oncologists, these findings could inform clinical trials and personalized medicine strategies, potentially integrating with existing protocols like those for leukemia or lymphoma. As immunotherapy gains traction in India amid rising cancer incidence, such advancements may enhance accessibility and efficacy, though further human studies are needed to validate safety and long-term outcomes.